STERIS

STERIS has established itself as a global leader in infection prevention, contamination control, and surgical support systems. The company provides an extensive portfolio of products—including capital equipment like sterilizers and washers—and services such as contract sterilization to healthcare providers, pharmaceutical manufacturers (including vaccine makers), biotechnology firms, research labs, medical device companies, and more. Its solutions are widely adopted across the globe with regulatory compliance to FDA cGMPs/ISO standards. Revenue surpassed $5 billion in FY2024 with over 18,000 employees worldwide.[1][3][5][7][8][9]

There are no clinical results or drug development programs since the company focuses on devices/services.

Recent milestones include major acquisitions such as Cantel Medical (2021), Key Surgical (2020), BD’s surgical instrumentation portfolio including V. Mueller™ instruments (2023), redomiciling to Ireland for tax purposes in 2019–2018,[7][8] joining the S&P500 index,[7] and rapid growth through both organic expansion and M&A.

During COVID‑19 pandemic response efforts in April 2020 it received FDA emergency use authorization for N95 mask reprocessing systems.[8]